Consejo Superior de Investigaciones Científicas posted this:Purine derivatives for the treatment of neurodegenerative diseasesCSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity makes them useful for the treatment of neurological diseases. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Control of neurodegenerative diseases with benzothiazole-benzamide derivativesCSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Piperidine derivatives for the control of Parkinson's and Alzheimer'sCSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Regulatory compounds of synaptic transmission for the treatment of neurological diseasesThe CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Centre Technology Transfer CITTRU posted this:A new method of the stereoselective synthesis of chosen medicinesThe subject of the offer is a new method of an asymmetric reduction of prochiral ketones and imines used in the synthesis of commonly used medicines, e.g. hormonal (eg. Cincalcet), pulmonary (eg. Salbutamol) and neurological ones (eg. Rasagiline).
Technology Transfer Office
Medical University of Łódź posted this:In vivo and in vitro experimental laboratory complexKeeping animals to research projects as well as own cultures. Cytotoxicity of a medical device in the form of an extract using in vitro assays: NRU, MTT, XTT, colony formation. Research projects in the field of neurology, orthopedics, toxicology, experimental surgery, oncology, metabolic and behavioral research (AnyMAZE, Morris pool, the cage of fear, IntelliCage) Conducting studies using GMOs. Training in procedures on laboratory animals. Renting test equipment.
uacoopera posted this:
Licensing Manager at uacoopera
uacoopera posted this:
Licensing Manager at uacoopera
Universidad de Alcalá-OTRI posted this:Development and method of construction of a new electrochemical sensor of Magnesium (Mg2 +), without the need to add organic salts, additives or organic solvents to the sampleThe research group in Bioelectrochemistry and Biosensors of the University of Alcalá in collaboration with the Textile Industry Research Association (AITEX) has developed an electrochemical sensor of magnesium (Mg2 +) and a construction method based on the formation of a polymeric three-dimensional network that allows the entrapment / immobilization of a selective indicator for Mg2 +, eriochrome black T, by the use of a crosslinking agent and a polymer. The combination of these three reagents allows the construction of the sensor on any conductive surface, avoiding the electro polymerization of the indicator. The resulting sensor allows to measure MG2 + in any type of samples, without the need to add organic salts, additives or organic solvents. The quantification of Mg2 + is done directly by incubating the sensor in the sample containing the analyte, resulting in a modification of the amperometric signal proportional to its concentration. This method has many applications especially in health and biomedical sector since Mg2 + participates in such important activities as neuronal, neuromuscular transmission, or regulation of blood pressure and plays a key role in various pathologies such as vascular and migraines headache. The group is looking for companies in the agro-food, bio-sanitary and environmental sectors, with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses.
Germans Trias i Pujol Health Sciences Research Institute posted this:Apotransferrin to treat strokeOur group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
Germans Trias i Pujol Health Sciences Research Institute posted this:Diagnostic biomarkers for dementia with Lewy BodiesThe present data provide a solid basis for the development of genetic biomarkers for the early identification of patients suffering from dementia with Lewy bodies and to classify them into specific molecular subtypes. One of the biomarkers correlates with the development of Lewy pathology in the brain and may be useful to monitor the success of possible alpha-synuclein antiaggregatory therapies.
University of Vigo posted this:Pyridazin-3(2H)-one Derivatives as Selective Inhibitors of Monoamine Oxidase-B Isoform (MAO-B)The pyridazine ring is a privileged fragment found in compounds with very different pharmacological properties, such as antihypertensive, antiplatelet, anti-inflammatory, antinociceptive, antidepressant, hypoglycemic, antiinfective or anticancer agents, many of them being pyridazin-3(2H)-one derivatives. The pyridazine ring is also included in polycyclic compounds acting as MAO-B inhibitors. However, simple pyridazin-3(2H)-one derivatives have not been described so far as selective MAO-B inhibitors. The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties that selectively inhibit the MAO-B activity and whose structure is unrelated to those currently available.
Centre Technology Transfer CITTRU posted this:New drug candidates for treatment of neuropathic pain and epilepsy.Despite the large number of available antiepileptic drugs, approximately 30% of patients fail to control seizures, and among those experiencing partial seizures (simple, complex, and secondarily generalized) the percentage is even higher at around 40%. Such a form of epilepsy is called drug resistance. One reason for the wide prevalence is the problem of insufficient efficacy of the currently available antiepileptic drugs. Also neuropathic pain in many cases is unable to control with use of currently used drugs. One of the possible reasons is that there are many mechanisms for the formation of the peripheral and central neuropathic pain, which frequently are still poorly known. Neuropathic pain is a serious clinical problem which affects up to 7 ‐ 8% of the population. Compounds included in the offer meet requirements for new, innovative drugs efficient in epilepsy and neuropathic pain cases which are still unmet medical needs (particularly drug resistant epilepsy and uncontrolled neuropathic pain – frequently of unknown etiology).
Technology Transfer Office
Centre Technology Transfer CITTRU posted this:New route to the synthesis of asenapine - an antipsychotic drugThe subject of the offer is an asymmetric synthesis of asenapine, a new atypical antipsychotic drug used to treat moderate to severe manic episodes in the course of bipolar disorder of the I type in adults.